

Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/AE89B5CA8AEEN.html>

Date: July 2021

Pages: 74

Price: US\$ 125.00 (Single User License)

ID: AE89B5CA8AEEN

Abstracts

Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company's product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline encompasses candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc Key Recent Developments

Jun 03,2021: Astellas Pharma: Reviewing capabilities for sustainable growth

Jun 02,2021: Astellas updates EHS (Environment, Health and Safety) Website

May 26,2021: Astellas announces new corporate strategic plan 2021

May 17,2021: Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting

May 13,2021: Astellas and Kyoto University Innovation Capital establish strategic alliance agreement

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Astellas Pharma Inc - Key Facts
Astellas Pharma Inc - Key Employees
Astellas Pharma Inc - Key Employee Biographies
Astellas Pharma Inc - Major Products and Services
Astellas Pharma Inc - History
Astellas Pharma Inc - Company Statement
Astellas Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Astellas Pharma Inc - Business Description
Product Category: Betanis/Myrbetriq/BETMIGA
Performance
Product Category: Other Products
Performance
Key Stats
Product Category: Prograf
Performance
Product Category: Vesicare
Performance
Product Category: Xtandi
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Performance
Geographical Segment: United States
Performance
R&D Overview
Astellas Pharma Inc - Corporate Strategy
Astellas Pharma Inc - SWOT Analysis

SWOT Analysis - Overview
Astellas Pharma Inc - Strengths
Astellas Pharma Inc - Weaknesses
Astellas Pharma Inc - Opportunities
Astellas Pharma Inc - Threats
Astellas Pharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Astellas Pharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 03, 2021: Astellas Pharma: Reviewing capabilities for sustainable growth
Jun 02, 2021: Astellas updates EHS (Environment, Health and Safety) Website
May 26, 2021: Astellas announces new corporate strategic plan 2021
May 17, 2021: Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting
May 13, 2021: Astellas and Kyoto University Innovation Capital establish strategic alliance agreement
May 13, 2021: Astellas and Kyoto University Innovation Capital establish Strategic Alliance Agreement
Apr 28, 2021: Astellas efforts against the spread of the Coronavirus Disease (COVID-19)
Apr 27, 2021: Astellas announces Financial Results for Fiscal Year 2020
Apr 27, 2021: Astellas Pharma: Launch of the IP Principles for Advancing Cures and Therapies
Apr 22, 2021: Zenith Epigenetics announces clinical collaboration with Astellas

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Astellas Pharma Inc, Key Facts
Astellas Pharma Inc, Key Employees
Astellas Pharma Inc, Key Employee Biographies
Astellas Pharma Inc, Major Products and Services
Astellas Pharma Inc, History
Astellas Pharma Inc, Other Locations
Astellas Pharma Inc, Subsidiaries
Astellas Pharma Inc, Joint Venture
Astellas Pharma Inc, Key Competitors
Astellas Pharma Inc, Ratios based on current share price
Astellas Pharma Inc, Annual Ratios
Astellas Pharma Inc, Annual Ratios (Cont...1)
Astellas Pharma Inc, Annual Ratios (Cont...2)
Astellas Pharma Inc, Interim Ratios
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Astellas Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Astellas Pharma Inc, Performance Chart (2017 - 2021)

Astellas Pharma Inc, Ratio Charts

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/AE89B5CA8AEEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AE89B5CA8AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970